Comparative Pharmacology
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus RONDOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BISMUTH SUBSALICYLATE METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE versus RONDOMYCIN.
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE vs RONDOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bismuth subsalicylate exerts antimicrobial and anti-inflammatory effects via binding to gastrointestinal mucosa and inhibiting prostaglandin synthesis; metronidazole inhibits DNA synthesis by forming nitro radical anions; tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Each dose consists of 2 capsules (each containing bismuth subsalicylate 262.4 mg, metronidazole 250 mg, and tetracycline hydrochloride 375 mg) taken orally 3 times daily (after meals) for 10 days.
150 mg orally twice daily or 300 mg orally once daily.
None Documented
None Documented
Bismuth subsalicylate: Bismuth component ~5 days (accumulation risk), salicylate 2–3 hours; Metronidazole: 8 hours (increased in hepatic impairment); Tetracycline HCl: 6–12 hours (prolonged in renal impairment).
Terminal elimination half-life is 6-8 hours in patients with normal renal function; may extend to 20-30 hours in severe renal impairment.
Bismuth subsalicylate: Renal excretion of salicylate and bismuth (bismuth largely fecal as insoluble sulfide); Metronidazole: Renal 60–80% (unchanged and metabolites), fecal 6–15%; Tetracycline HCl: Renal 60% unchanged, fecal 40% (biliary and direct excretion).
Renal (40-50% unchanged), biliary/fecal (10-20% as metabolites and unchanged drug). Approximately 30% undergoes enterohepatic circulation.
Category D/X
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic